Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Nucleai is a leading AI-powered spatial biology company on a mission to transform drug development and clinical treatment decisions in oncology and other diseases. Their platform leverages proprietary computer vision and machine learning algorithms to analyze pathology images, unlocking spatial insights from tissue data. This enables biopharmaceutical companies to develop more effective drugs and helps clinicians make better-informed treatment decisions, ultimately aiming to improve patient outcomes. Nucleai focuses on identifying novel biomarkers and stratifying patients with high precision.
Serves as the central hub for research and development, corporate strategy, and global operations management.
Located in a modern tech-centric area, fostering collaboration and innovation within a state-of-the-art facility.
A dynamic, fast-paced, and innovative environment focused on cutting-edge AI and biotech research. Emphasizes collaboration, problem-solving, and a mission-driven approach to impacting healthcare.
The Tel Aviv headquarters is crucial for tapping into Israel's rich talent pool in AI, computer science, and biomedical research, driving the company's technological advancements and core innovations.
Nucleai supports its global operations primarily from its headquarters in Tel Aviv, Israel, and its US office in Cambridge, MA. While these are its main physical hubs, the company collaborates with biopharmaceutical companies, research institutions, and clinical sites internationally. Its AI-powered platform and services are utilized by partners across North America, Europe, and other regions, supporting drug development pipelines and clinical studies worldwide through cloud-based solutions and remote expert consultations.
Aluf Kalman Magen St 3
Tel Aviv-Yafo
Tel Aviv District
Israel
Address: One Broadway, 14th Floor, Cambridge, MA 02142, USA
To expand Nucleai's presence in the North American market, engage with key industry players, and facilitate local customer support and research activities for its AI-driven pathology solutions.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Nucleai' leadership includes:
Nucleai has been backed by several prominent investors over the years, including:
Over the last 12 months (from mid-2023 to mid-2024), Nucleai has strengthened its leadership team with key appointments, particularly in Finance, People, and Marketing, reflecting its growth and expansion phase. No major executive departures have been publicly announced during this period.
Discover the tools Nucleai uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Nucleai likely utilizes common corporate email formats. Based on industry standards and publicly available information, a prevalent format appears to be combining the employee's first name and last name, or just the first name, separated by a dot or directly followed by '@nucleai.com'.
firstname.lastname@nucleai.com
Format
john.doe@nucleai.com
Example
85%
Success rate
Business Wire • January 10, 2024
Nucleai partnered with GoPath Diagnostics to deploy Nucleai's AI-powered spatial analysis platform within GoPath's pathology services, aiming to enhance cancer diagnosis and treatment strategies by providing deeper insights from pathology slides....more
PR Newswire • October 26, 2023
Nucleai published research in Modern Pathology showcasing its AI model's ability to predict Homologous Recombination Deficiency (HRD) status in high-grade ovarian cancer patients using standard H&E-stained pathology slides, potentially streamlining biomarker testing....more
PR Newswire • May 10, 2023
Nucleai announced the expansion of its spatial biology atlas by incorporating high-plex multi-modal data, aiming to accelerate the discovery of novel drug targets and biomarkers through more comprehensive tissue analysis....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Nucleai, are just a search away.